HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals In Depth: December 2012

Executive Summary

Biogen and Isis teamed up in their third antisense deal. Baxter paid $4 billion for its partner, dialysis company Gambro. Biopharma financing was boosted by Amarin’s large debt offering and a couple $100 million-plus FOPOs. Volcano’s $445 million notes deal drove device fundraising to $604 million.

You may also be interested in...



Novo Executive Calls For ‘Real AMR Action’ In Davos

The Novo Nordisk Foundation is sponsoring a panel at Davos this week on finding solutions to the global crisis on antimicrobial resistance – and hopes world leaders will listen.

Roche Gears Up For Potential Neuroscience Breakthroughs

Neuroscience could be this decade’s big growth story, but clinical and market access challenges differ to oncology.

Appeals Court Holds US Humira Patents Invalid

The US Court of Appeals for the Federal Circuit has upheld a series of inter partes review decisions from 2017 in which three Humira patents were found invalid by the Patent Trial and Appeal Board within the US Patent and Trademark Office.

Topics

Related Companies

UsernamePublicRestriction

Register

IV003997

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel